Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank Disease ID
1 DDC [7] Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Cocaine addiction D00558 Carbidopa [9] 2, 4, 6, 13, 17, 90, 140, 164, 201
2 DDC [7] Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Cocaine addiction D03082 Benserazide [1] 6
3 DRD1 [6] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Morphine addiction D00059 Levodopa [8] 2, 4, 6, 17, 90, 140, 164, 201
4 DRD1 [6] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Morphine addiction D00502 Pergolide [1] 6
5 DRD1 [6] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Morphine addiction D00633 Dopamine [4] 6, 7, 74, 299
6 DRD1 [6] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Morphine addiction D01044 Flupentixol [1] 97
7 DRD1 [6] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Morphine addiction D02004 Apomorphine [3] 5, 6, 7
8 DRD1 [6] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Morphine addiction D07460 Apomorphine [3] 5, 6, 7
9 DRD1 [6] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Morphine addiction D07870 Dopamine [4] 6, 7, 74, 299
10 DRD1 [6] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Morphine addiction D08339 Pergolide [1] 6
11 DRD1 [6] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Morphine addiction D09886 Dexpramipexole [1] 2
12 DRD1 [6] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Morphine addiction D11431 Tavapadon [1] 6
13 DRD1 [6] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Morphine addiction D11839 Foslevodopa [1] 6
14 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D00059 Levodopa [8] 2, 4, 6, 17, 90, 140, 164, 201
15 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D00136 Haloperidol [1] 8
16 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D00270 Chlorpromazine [1] 254
17 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D00426 Risperidone [5] 8, 156, 179, 187, 206
18 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D00454 Olanzapine [2] 2, 8
19 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D00458 Quetiapine [2] 6, 13
20 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D00502 Pergolide [1] 6
21 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D00559 Pramipexole [3] 2, 6, 20
22 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D00560 Pimozide [1] 2
23 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D00633 Dopamine [4] 6, 7, 74, 299
24 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D00702 Buspirone [3] 6, 51, 179
25 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D00726 Metoclopramide [1] 51
26 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D00780 Bromocriptine [2] 6, 74
27 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D00784 Ropinirole [4] 2, 6, 74, 309
28 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D00789 Chlorpromazine [1] 254
29 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D00799 Trifluoperazine [2] 283, 284
30 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D00987 Cabergoline [3] 6, 74, 75
31 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D01044 Flupentixol [1] 97
32 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D01164 Aripiprazole [2] 6, 206
33 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D01226 Sulpiride [5] 2, 6, 17, 46, 70
34 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D01348 Terguride [2] 51, 86
35 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D01448 Trifluoperazine [2] 283, 284
36 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D01462 Lisuride [2] 6, 86
37 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D01745 Domperidone [5] 6, 13, 17, 51, 230
38 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D01898 Haloperidol [1] 8
39 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D02004 Apomorphine [3] 5, 6, 7
40 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D02213 Metoclopramide [1] 51
41 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D03165 Bromocriptine [2] 6, 74
42 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D03274 Chlorpromazine [1] 254
43 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D04034 Chlorpromazine [1] 254
44 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D05008 Metoclopramide [1] 51
45 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D05575 Pramipexole [3] 2, 6, 20
46 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D05768 Rotigotine [2] 6, 127
47 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D06623 Olanzapine [2] 2, 8
48 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D07305 Piribedil [1] 6
49 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D07309 Melperone [1] 6
50 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D07460 Apomorphine [3] 5, 6, 7
51 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D07593 Buspirone [3] 6, 51, 179
52 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D07868 Domperidone [5] 6, 13, 17, 51, 230
53 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D07870 Dopamine [4] 6, 7, 74, 299
54 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D08132 Lisuride [2] 6, 86
55 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D08339 Pergolide [1] 6
56 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D08456 Quetiapine [2] 6, 13
57 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D08489 Ropinirole [4] 2, 6, 74, 309
58 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D08549 Sulpiride [5] 2, 6, 17, 46, 70
59 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D08590 Tiapride [1] 8
60 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D08636 Trifluoperazine [2] 283, 284
61 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D09397 Pardoprunox [1] 6
62 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D09886 Dexpramipexole [1] 2
63 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D09953 Pridopidine [3] 2, 6, 8
64 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D09997 Cariprazine [1] 21
65 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D11839 Foslevodopa [1] 6
66 GRIA2 [11] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
67 GRIA2 [11] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
68 GRIA2 [11] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D02696 Talampanel [2] 2, 6
69 GRIA2 [11] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D08964 Perampanel [3] 2, 6, 144
70 GRIN1 [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D00711 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
71 GRIN1 [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
72 GRIN1 [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D00777 Amantadine [4] 6, 8, 13, 127
73 GRIN1 [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D00848 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
74 GRIN1 [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D02780 Acamprosate [2] 6, 206
75 GRIN1 [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
76 GRIN1 [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D03744 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
77 GRIN1 [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D04905 Memantine [7] 2, 6, 8, 13, 49, 127, 205
78 GRIN1 [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D07058 Acamprosate [2] 6, 206
79 GRIN1 [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D07283 Esketamine [3] 2, 4, 70
80 GRIN1 [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D07441 Amantadine [4] 6, 8, 13, 127
81 GRIN1 [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
82 GRIN1 [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D08174 Memantine [7] 2, 6, 8, 13, 49, 127, 205
83 GRIN1 [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D09917 Latrepirdine [1] 8
84 GRIN2A [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D00711 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
85 GRIN2A [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
86 GRIN2A [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D00777 Amantadine [4] 6, 8, 13, 127
87 GRIN2A [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D00848 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
88 GRIN2A [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D02780 Acamprosate [2] 6, 206
89 GRIN2A [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
90 GRIN2A [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D03744 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
91 GRIN2A [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D04905 Memantine [7] 2, 6, 8, 13, 49, 127, 205
92 GRIN2A [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D07058 Acamprosate [2] 6, 206
93 GRIN2A [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D07283 Esketamine [3] 2, 4, 70
94 GRIN2A [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D07441 Amantadine [4] 6, 8, 13, 127
95 GRIN2A [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
96 GRIN2A [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D08174 Memantine [7] 2, 6, 8, 13, 49, 127, 205
97 GRIN2A [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D09917 Latrepirdine [1] 8
98 GRIN2B [13] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D00711 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
99 GRIN2B [13] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
100 GRIN2B [13] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D00777 Amantadine [4] 6, 8, 13, 127
101 GRIN2B [13] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D00848 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
102 GRIN2B [13] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D02780 Acamprosate [2] 6, 206
103 GRIN2B [13] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
104 GRIN2B [13] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D03744 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
105 GRIN2B [13] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D04905 Memantine [7] 2, 6, 8, 13, 49, 127, 205
106 GRIN2B [13] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D07058 Acamprosate [2] 6, 206
107 GRIN2B [13] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D07283 Esketamine [3] 2, 4, 70
108 GRIN2B [13] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D07441 Amantadine [4] 6, 8, 13, 127
109 GRIN2B [13] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
110 GRIN2B [13] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D08174 Memantine [7] 2, 6, 8, 13, 49, 127, 205
111 GRIN2B [13] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D09917 Latrepirdine [1] 8
112 GRIN2C [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D00711 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
113 GRIN2C [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
114 GRIN2C [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D00777 Amantadine [4] 6, 8, 13, 127
115 GRIN2C [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D00848 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
116 GRIN2C [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D02780 Acamprosate [2] 6, 206
117 GRIN2C [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
118 GRIN2C [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D03744 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
119 GRIN2C [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D04905 Memantine [7] 2, 6, 8, 13, 49, 127, 205
120 GRIN2C [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D07058 Acamprosate [2] 6, 206
121 GRIN2C [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D07283 Esketamine [3] 2, 4, 70
122 GRIN2C [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D07441 Amantadine [4] 6, 8, 13, 127
123 GRIN2C [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
124 GRIN2C [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D08174 Memantine [7] 2, 6, 8, 13, 49, 127, 205
125 GRIN2C [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D09917 Latrepirdine [1] 8
126 GRIN2D [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D00711 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
127 GRIN2D [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
128 GRIN2D [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D00777 Amantadine [4] 6, 8, 13, 127
129 GRIN2D [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D00848 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
130 GRIN2D [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D02780 Acamprosate [2] 6, 206
131 GRIN2D [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
132 GRIN2D [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D03744 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
133 GRIN2D [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D04905 Memantine [7] 2, 6, 8, 13, 49, 127, 205
134 GRIN2D [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D07058 Acamprosate [2] 6, 206
135 GRIN2D [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D07283 Esketamine [3] 2, 4, 70
136 GRIN2D [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D07441 Amantadine [4] 6, 8, 13, 127
137 GRIN2D [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
138 GRIN2D [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D08174 Memantine [7] 2, 6, 8, 13, 49, 127, 205
139 GRIN2D [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D09917 Latrepirdine [1] 8
140 MAOA [11] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction D00505 Phenelzine [1] 6
141 MAOA [11] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction D02561 Moclobemide [1] 6
142 MAOA [11] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction D02579 Iproniazid [1] 6
143 MAOA [11] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction D05458 Phentermine [1] 97
144 MAOA [11] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction D05459 Phentermine [1] 97
145 MAOA [11] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction D08349 Phenelzine [1] 6
146 MAOB [11] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction D00505 Phenelzine [1] 6
147 MAOB [11] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction D00785 Selegiline [1] 6
148 MAOB [11] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction D02562 Rasagiline [7] 2, 5, 6, 13, 17, 58, 66
149 MAOB [11] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction D02579 Iproniazid [1] 6
150 MAOB [11] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction D03731 Selegiline [1] 6
151 MAOB [11] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction D05458 Phentermine [1] 97
152 MAOB [11] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction D05459 Phentermine [1] 97
153 MAOB [11] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction D08349 Phenelzine [1] 6
154 MAOB [11] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction D08469 Rasagiline [7] 2, 5, 6, 13, 17, 58, 66
155 MAOB [11] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction D10158 Safinamide [2] 6, 17
156 MAOB [11] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction D10829 Rasagiline [7] 2, 5, 6, 13, 17, 58, 66
157 NFKB1 [59] MAPK signaling pathway, Ras signaling pathway, NF-kappa B signaling pathway, HIF-1 signaling pathway, Sphingolipid signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Prolactin signaling pathway, Relaxin signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Viral carcinogenesis, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, Small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease, Diabetic cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D01146 Iguratimod [4] 46, 51, 53, 271
158 RELA [59] MAPK signaling pathway, Ras signaling pathway, NF-kappa B signaling pathway, HIF-1 signaling pathway, Sphingolipid signaling pathway, Mitophagy - animal, PI3K-Akt signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Prolactin signaling pathway, Relaxin signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Viral carcinogenesis, Pancreatic cancer, Prostate cancer, Small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease, Diabetic cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D12181 Edasalonexent [1] 113
159 SLC6A3 [5] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction D00817 Bupropion [5] 8, 18, 21, 96, 171
160 SLC6A3 [5] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction D01296 Methylphenidate [7] 6, 13, 34, 84, 113, 179, 206
161 SLC6A3 [5] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction D03215 Armodafinil [3] 6, 13, 84
162 SLC6A3 [5] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction D04999 Methylphenidate [7] 6, 13, 34, 84, 113, 179, 206
163 SLC6A3 [5] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction D05458 Phentermine [1] 97
164 SLC6A3 [5] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction D05459 Phentermine [1] 97
165 SLC6A3 [5] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction D07591 Bupropion [5] 8, 18, 21, 96, 171
166 SLC6A3 [5] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction D07938 Bupropion [5] 8, 18, 21, 96, 171
167 SLC6A3 [5] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction D08130 Lisdexamfetamine [1] 13
168 SLC18A2 [5] Synaptic vesicle cycle, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction D08575 Tetrabenazine [1] 8
169 SLC18A2 [5] Synaptic vesicle cycle, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction D10675 Valbenazine [1] 8
170 SLC18A2 [5] Synaptic vesicle cycle, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction D10701 Deutetrabenazine [1] 8